Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Spebrutinib |
| Trade Name | |
| Synonyms | AVL-292|CC-292 |
| Drug Descriptions |
Spebrutinib (CC-292) is a covalent inhibitor of Btk that decreases Btk kinase activity and activation of downstream signaling, resulting in reduced B-cell proliferation (PMID: 24518207, PMID: 31721017). |
| DrugClasses | BTK inhibitor 38 |
| CAS Registry Number | 1202757-89-8 |
| NCIT ID | C97037 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| CC-122 + Spebrutinib | CC-122 Spebrutinib | 0 | 1 |
| Onatasertib + Spebrutinib | Onatasertib Spebrutinib | 0 | 1 |
| Spebrutinib | Spebrutinib | 0 | 0 |